The Evolving Power of Immunotherapy
Symposium
Symposium

The Evolving Power of Immunotherapy

Transforming Outcomes in Advanced Lung Cancer

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your knowledge of current and emerging use of checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) and how to optimize immunotherapy benefit in this disease. Along with presentations of the latest clinical trial data, this symposium will have an interactive case-based expert panel discussion facilitating a better understanding of how immunotherapy (combinations) should be applied in clinical practice.

Date and Location

Friday, 13 April 2018
18.40 – 19.40

Room A
Palexpo
Route François-Peyrot 30
Geneva, Switzerland

Date/Time

Date/Time

Friday, 13 April 2018
18.40 – 19.40

Location

Location

Geneva, Switzerland

CME

CME

18.40 Welcome and introduction
Solange Peters, MD, PhD
18.45 Are you up to date with immunotherapy in lung cancer?
Solange Peters, MD, PhD
18.50 Use of immune checkpoint inhibitors in advanced NSCLC: Successes and challenges
Fabrice Barlesi, MD, PhD
19.07 Next steps in NSCLC management: Integrating immunotherapy combinations in clinical practice
Martin Reck, MD, PhD
19.24 Interactive clinical scenarios: Applying knowledge to practice
Solange Peters, MD, PhD, and faculty panel
19.38 prIME Points™
Solange Peters, MD, PhD
19.40 Adjourn

    Chair

  • Solange Peters, MD, PhDUniversity of Lausanne
    Lausanne, Switzerland
  • Faculty

  • Fabrice Barlesi, MD, PhDAssitance Publique
    Hôpitaux De Marseille
    Marseille, France
  • Martin Reck, MD, PhDLungenClinic Grosshansdorf
    Grosshansdorf, Germany

This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Select the optimal immunotherapy approach for patients with advanced NSCLC, and assess the role of PD-L1 expression and other emerging biomarkers for response to immunotherapy
  • Explain patterns of response to immunotherapy and manage specific immune-related adverse events
  • Describe emerging immunotherapy combination strategies and how to integrate them in clinical practice

This educational activity is supported by F. Hoffmann-La Roche Ltd.

Continuing Education

An application has been made to the EACCME® for CME Accreditation of this event.

Good CME

The Evolving Power of Immunotherapy - prIME Oncology

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.